Poitiers University Hospital: Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials

The registry lists 10 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies with Poitiers University Hospital as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 4Phase 3 2Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT TrialEnrolling by invitationNCT06646978
• International Chronic Myeloid Leukemia Pediatric StudyRecruitingNCT01281735
• Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune SystemActive, not recruitingNCT05753384Phase 3
• Innate T Cells and TKI DiscontinuationActive, not recruitingNCT04645706
• Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT01872442Phase 2
• Glivec in Pediatric Chronic Myeloid Leukemia (CML)CompletedNCT00845221Phase 4
• Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous PatientsTerminatedNCT00219765Phase 1/2
• Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 YearsCompletedNCT00219752Phase 2
• STI571 ProspectIve RandomIzed Trial: SPIRITCompletedNCT00219739Phase 3
• Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell TransplantationCompletedNCT00219726Phase 2